Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Penicillamine
Drug ID BADD_D01709
Description Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Indications and Usage For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis.
Marketing Status approved
ATC Code M01CC01
DrugBank ID DB00859
KEGG ID D00496
MeSH ID D010396
PubChem ID 5852
TTD Drug ID D08HZC
NDC Product Code 59285-014; 76339-159; 0254-2000; 68682-020; 70010-907; 0591-4171; 68022-7041; 72640-012; 25010-705; 60505-4696; 62559-970; 71205-916; 0037-4401; 62207-013; 71052-491; 43598-634; 51991-974; 70748-153; 42973-230; 51552-1096; 49884-146; 68475-201; 59651-245; 70159-004; 76003-0870
UNII GNN1DV99GX
Synonyms Penicillamine | Mercaptovaline | D-Penicillamine | D Penicillamine | Dimethylcysteine | beta,beta-Dimethylcysteine | beta,beta Dimethylcysteine | D-3-Mercaptovaline | D 3 Mercaptovaline | Metalcaptase | Cuprimine | Copper Penicillaminate | Penicillaminate, Copper | Cuprenil
Chemical Information
Molecular Formula C5H11NO2S
CAS Registry Number 771431-20-0
SMILES CC(C)(C(C(=O)O)N)S
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.003--
Abortion spontaneous18.01.04.0010.000051%Not Available
Ageusia17.02.07.001; 07.14.03.003--Not Available
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000077%
Anxiety19.06.02.002--
Aplasia pure red cell10.02.01.003; 01.03.03.001--Not Available
Aplastic anaemia01.03.03.002--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.0010.000113%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrophy08.03.04.001--Not Available
Blunted affect19.04.01.003--Not Available
Body temperature increased13.15.01.001--Not Available
Breast enlargement21.05.04.001--Not Available
Breast hyperplasia21.05.01.007--Not Available
Cheilosis23.03.03.026; 07.05.01.002--Not Available
Cholestasis09.01.01.001--Not Available
Coagulopathy01.01.02.001--Not Available
Condition aggravated08.01.03.0040.000154%Not Available
Cutaneous vasculitis24.12.04.008; 23.06.02.001; 10.02.02.003--Not Available
Cutis laxa23.03.02.009; 15.06.01.007--Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dermatomyositis15.05.01.002; 10.04.04.027; 23.03.02.001--Not Available
Diarrhoea07.02.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene